High Resolution Diffusion Weighted Imaging in Prostate

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Oct 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging technique called high resolution diffusion-weighted imaging (hrDWI) for men with prostate cancer or other prostate diseases. Researchers believe that hrDWI may provide clearer and more accurate images of the prostate compared to the standard technique, conventional diffusion-weighted imaging (cDWI). This could help doctors make better decisions about diagnosis and treatment for prostate cancer.

To join this study, participants must be men who have already had a standard MRI scan that includes both cDWI and hrDWI, and they should have complete medical information available. However, men who are currently taking certain medications for prostate conditions, or who have had previous prostate surgery or biopsies, cannot participate. If eligible, participants can expect to undergo additional imaging and contribute to important research that could improve prostate cancer diagnosis in the future. The trial is currently recruiting men aged 18 and older.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who underwent standard MR scanning including T2WI, cDWI , hrDWI and respective calculated apparent diffusion coefficient (ADC) maps;
• • 2. Complete clinical information.
• Exclusion Criteria:
• • Men were excluded if they were using 5-alpha-reductase inhibitors at time of examination or has used such during the previous six months; or if they had a previous history of prostatic biopsy, prostatic surgery, or treatment for PCa